Cephalon stays at neutral by Merrill

Cephalon, Inc was maintained at neutral by Merrill Lynch analyst Gregg Gilbert on safety information in a briefing from the Food and Drug Administration Advisory Committee regarding its meeting on Sparlon to be held on Thursday. Merrill's model assumes Sparlon approval and launch in the second quarter. Shares of the Frazer, Pa., pharmaceutical company were up $1.45, or 2.02%, at $73.31 on volume of 22,529,097 shares versus the three-month running average of 3,005,350 shares. (Nasdaq: CEPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.